Sanitor Corporation was cited for CGMP violations after hand sanitizer failed microbial testing and skin-bleaching drugs were sold without approval.
What happened
FDA inspected Sanitor Corporation's drug manufacturing facility in Stanton, California, from May 25, 2021, to June 3, 2021. Investigators found multiple hand sanitizer batches failed microbial total plate count testing with "Too Numerous to Count" results, and the quality unit approved adding a preservative and released batches, including one shipped before microbiological results were received. FDA also cited unapproved skin-bleaching/lightening drug products, misbranding, and failure to list hydroquinone products.
What FDA found
The quality unit did not adequately investigate hand sanitizer batches that failed microbial testing, allowed preservative to be added to failed or untested batches, and approved a shipment before microbiological results were available.
21 CFR 211.22The company released reworked and reformulated hand sanitizer without demonstrating the antimicrobial effectiveness of the added preservative.
21 CFR 211.160(b)The stability program was inadequate, including an unsupported bracketing approach for hydroquinone products implemented without adequate change control.
21 CFR 211.22Batch records were not recorded contemporaneously, and a verifier was documented as present when they were not at work.
21 CFR 211.22The FTIR spectroscopy computer system lacked controls to prevent deletion of raw data and lacked adequate password protection.
21 CFR 211.68(b)Skin bleaching/lightening products were marketed as unapproved new drugs, an acne treatment was misbranded, and hydroquinone products were not listed with FDA.
FD&C Act sections 505(a), 502(c), 510(j)
What FDA wants
FDA asks the company to provide comprehensive independent assessments, investigations, CAPA plans, and remediation for its quality, laboratory, stability, documentation, and data-integrity systems, and to take rapid corrective action if its hand sanitizer review finds failing products were distributed. The provided letter text does not state a response deadline.
Who should pay attention
- companies that buy hand sanitizer from contract manufacturers
- brands selling skin-lightening or hydroquinone products
- quality teams at OTC drug contract manufacturers
This is a summary. Read the original letter on fda.gov.